Skip to results

Area of interest

Area of interest

Type (1 selected)


Guidance programme (1 selected)

Guidance programme

Showing 101 to 125 of 283

Guidance and quality standards awaiting development
Galcanezumab for migraine TS ID 10663Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease TS ID 10668Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All